Must-reads for professionals working in the field of Immunologic therapies and cancer
For professionals working in the fields of immunologic therapies and cancer. We curate thousands of sources from around the world and bring you our newsletter with the most important and relevant news twice a week.
StreetInsider.com … Eisai Co. Ltd. and Merck announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Eisai’s multiple receptor tyrosine kinase inhibitor LENVIMA in combination with Merck’s anti-PD-1 therapy KEYTRUDA for the potential treatment…
BusinessWire.com … THERACLION, a company specialized in leading-edge medical equipment for echotherapy, today announced that Dr. Patrick M. Dillon, MD, UVA Medical Center, Charlottesville, USA, primary investigator of the echotherapy/ immunotherapy combination trial has been accepted in the official scientific program of the ASCO…
GlobeNewsWire.com … Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical company, to develop novel multi-specific antibodies for…
Immuno-oncologynews.com … Targovax’s immunotherapy for solid tumors has passed its first clinical trial safety review. The company is conducting a Phase 1b trial of TG02 alone, and in combination with Merck’s Keytruda, as a treatment for colorectal cancer stemming from a Ras protein mutation. TG02 is a cancer vaccine designed to trigger an immune response to a tumor…
P&T Community… Pembrolizumab significantly improved recurrence-free survival compared with placebo in a phase 3 trial investigating the anti-PD-1 medication as monotherapy for surgically resected high-risk melanoma. Based on an interim analysis and following review…